Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâ€™s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-14	SEK 1.080	-0.92%	16,850
26-07-13	SEK 1.090	+0.93%	90,400
26-07-10	SEK 1.080	-3.57%	66,511
26-07-09	SEK 1.120	+5.16%	29,500
26-07-08	SEK 1.065	-1.84%	24,778

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-14 EDT			5-day change	1st Jan Change
1.080 ^SEK	-0.92%		-0.46%	-5.26%

06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI
06-22	Iconovo, Lonza Finalize Long-term Strategic Collaboration	MT

Market Cap	104M 10.78M 9.42M 8.71M 8.05M 15.15M 1.04B 15.43M 40.75M 507M 40.5M 39.6M 1.75B	P/E 2026 *	-27x	P/E 2027 *	-3.09x
Enterprise Value	64.87M 6.73M 5.88M 5.44M 5.03M 9.46M 647M 9.63M 25.45M 317M 25.29M 24.73M 1.09B	EV / Sales 2026 *	2.24x	EV / Sales 2027 *	-
Free-Float	39.74%	Yield 2026 *	-	Yield 2027 *	-

06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI
06-22	Iconovo, Lonza Finalize Long-term Strategic Collaboration	MT
04-24	Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Iconovo Q1 net sales up at 0.7 mln SEK	RE
04-14	Iconovo appoints Anders Mañsson as CEO	RE
04-14	Iconovo AB Appoints Anders Månsson as Permanent CEO, Effective April 14, 2026	CI
03-17	Iconovo says no TO 1 was used for subscription	RE
03-02	Iconovo announces final outcome of rights issue	RE
02-25	Iconovo and Lonza sign LOI regarding strategic collaboration	RE
02-24	Iconovo AB (Publ.) and Lonza Signs LOI Regarding Strategic Collaboration	CI
02-12	Iconovo Q4 net sales SEK 504,000	RE
02-12	Iconovo AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-15	Iconovo Secures SEK1 Million Feasibility Study Contract for Nasal Delivery Platform	MT

07-03	Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB	AQ
06-29	Iconovo terminates liquidity provider agreement	AQ
06-22	Iconovo and Lonza sign Strategic Collaboration Agreement	AQ
04-24	Iconovo: Limited progress – Q1 review	AQ
04-14	Anders Månsson is appointed CEO	AQ

Iconovo AB Stock

Stocks

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Valuation: Iconovo AB

Chart: Iconovo AB

Latest news : Iconovo AB

Analysts' recommendations: Iconovo AB

Press Releases: Iconovo AB

Quotes and Performance

Course Extremes

Managers and Directors: Iconovo AB

Latest insider transactions

Medical Supplies

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 day	-0.92%
1 week	-0.46%
Current month	+2.86%
1 month	-11.11%
3 months	-5.68%
6 months	-10.00%
Current year	-5.26%

1 week	1.07	1.12
1 month	0.91	1.26
Current year	0.91	1.44
1 year	0.91	2.79
3 years	0.91	25.2
5 years	0.91	97.8
10 years	0.91	99.8

Manager	Title	Age	Since
Anders Månsson CEO	Chief Executive Officer	59	2025-10-30
Henrik Simonsen DFI	Director of Finance/CFO	63	2023-03-31
Mikael Arinder COO	Chief Operating Officer	62	2015-12-31

Director	Title	Age	Since
Mats Håkan Johansson CHM	Chairman	65	2012-12-31
Orest Lastow BRD	Director/Board Member	62	2012-12-31
Berndt David Lennart Axelsson BRD	Director/Board Member	67	2012-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-09-21	Mats Håkan Johansson	Buy	Founder	500	0.0057%
22-09-20	Johan Wäborg	Buy	Chief Executive Officer	1,000	0.0113%
22-09-15	Agneta Walhagen	Buy	Director	840	0.0095%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICONOVO AB	-0.92%	-0.46%	-48.82%	-95.73%	10.78M
COLOPLAST A/S	-2.51%	-2.46%	-34.07%	-50.54%	13.66B
INTCO MEDICAL TECHNOLOGY CO., LTD.	+1.14%	-1.10%	+65.66%	+108.84%	4.31B
ZHENDE MEDICAL CO., LTD.	+1.96%	-0.90%	+323.38%	+211.64%	3.46B
WINNER MEDICAL CO., LTD.	+2.48%	+0.11%	-28.71%	-33.40%	2.41B
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	+3.65%	+3.64%	-42.42%	-67.43%	1.89B
JAFRON BIOMEDICAL CO.,LTD.	+1.97%	+2.10%	-26.80%	-24.77%	1.89B
TOP GLOVE CORPORATION BHD.	0.00%	-1.50%	-5.76%	-29.19%	1.29B
GVS S.P.A.	0.00%	+6.76%	-14.71%	-12.84%	979M
RIVERSTONE HOLDINGS LIMITED	+2.34%	+6.71%	+28.68%	+40.00%	982M
Average	+1.04%	+0.17%	+21.64%	+4.66%	3.09B
Weighted average by Cap.	-0.10%	+0.95%	+24.04%	+7.92%

	2026 *	2027 *
Net sales	29M 3.01M 2.63M 2.43M 2.25M 4.23M 289M 4.31M 11.38M 142M 11.31M 11.06M 487M	-
Net income	-3M -311K -272K -252K -232K -438K -29.91M -446K -1.18M -14.65M -1.17M -1.14M -50.43M	-34M -3.53M -3.08M -2.85M -2.63M -4.96M -339M -5.05M -13.34M -166M -13.26M -12.96M -572M
Net Debt	-39M -4.05M -3.54M -3.27M -3.02M -5.69M -389M -5.79M -15.3M -190M -15.21M -14.87M -656M	1M 104K 90.71K 83.85K 77.47K 146K 9.97M 149K 392K 4.88M 390K 381K 16.81M